Assay to identify compounds that alter apolipoprotein E expression
US6428950B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 22, 1999 |
| Grant date | Aug 6, 2002 |
| Priority date | — |
| Expiry date | Nov 22, 2019 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/20
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a method of assaying for and arresting, preventing and/or reversing the impairment of central and peripheral nervous system function comprising reducing &bgr;-amyloid plaque burden by the administration of compounds that reduce apoE expression. The compounds used in the method of the invention may be: 1) inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase; 2) inhibitors of cholesterol biosynthesis; 3) inhibitors of protein isoprenylation, specifically geranylgeranylation; and/or 4) inhibitors of NF-&kgr;B activation or function. Assays for compounds with inhibit apoE expression from microglial cells are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.